Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04QXF
|
|||
| Former ID |
DIB014001
|
|||
| Drug Name |
Anti-CD3 monoclonal antibody
|
|||
| Synonyms |
Anti-CD3 monoclonal antibody (oral, autoimmune/inflammatory disease), NasVax; Anti-CD3 monoclonal antibody (oral, autoimmune/inflammatory disease/HCV infection); ACD3 mAb (oral, autoimmune/inflammatory disease/HCV infection), NasVax/Centocor Ortho Biotech; Anti-CD3 monoclonal antibody + glycolipids (oral, autoimmune disease), Harvard Medical School/Hadassah; Anti-CD3 monoclonal antibody + glycolipids (oral, autoimmune/inflammatory disease), NasVax; Anti-CD3 monoclonal antibody (oral, autoimmune/inflammatory disease/HCV infection), NasVax/Centocor Ortho Biotech
Click to Show/Hide
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 3 | [1] | |
| Company |
Harvard Medical School
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop. Expert Rev Clin Immunol. 2013 Feb;9(2):95-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.